A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma

Andrew Menzies-Gow 1 2, David J Jackson 3, Mona Al-Ahmad 4, Eugene R Bleecker 5, Francisco de Borja G Cosio Piqueras 6, Stephen Brunton 7, Giorgio Walter Canonica 8 9, Charles K N Chan 10, John Haughney 11, Steve Holmes 12, Janwillem Kocks 13 14 15, Tonya Winders 16 17

Affiliations

01 December 2022

-

doi: 10.1007/s12325-022-02340-w

Abstract

Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5-10% of patients with asthma, approximately 17-34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care.

Keywords: Health care; Patient advocacy; Severe asthma.

Figures

Fig. 1 The disease management cycle for asthma care (adapted from GINA 2021) [1]

Fig. 1 The disease management cycle for asthma care (adapted from GINA 2021) [1]

Fig. 2 Patient perspective on severe asthma (adapted from Menzies-Gow et al. 2018) [18]

Fig. 2 Patient perspective on severe asthma (adapted from Menzies-Gow et al. 2018) [18]

Similar articles

Global Quality Standard for Identification and Management of Severe Asthma.

Haughney J, Winders TA, Holmes S, Chanez P, Saul H, Menzies-Gow A; PRECISION Improve Access to Better Care Task Force.Adv Ther. 2020 Sep;37(9):3645-3659. doi: 10.1007/s12325-020-01450-7. Epub 2020 Jul 28.PMID: 32725419 Free PMC article.

A Charter to Improve Patient Care in Severe Asthma.

Menzies-Gow A, Canonica GW, Winders TA, Correia de Sousa J, Upham JW, Fink-Wagner AH.Adv Ther. 2018 Oct;35(10):1485-1496. doi: 10.1007/s12325-018-0777-y. Epub 2018 Sep 4.PMID: 30182174 Free PMC article.

The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.

Walter H, Sadeque-Iqbal F, Ulysse R, Castillo D, Fitzpatrick A, Singleton J.JBI Database System Rev Implement Rep. 2015 Oct;13(10):69-81. doi: 10.11124/jbisrir-2015-2335.PMID: 26571284

Severe asthma: Current management, targeted therapies and future directions-A roundtable report.

McDonald VM, Maltby S, Reddel HK, King GG, Wark PA, Smith L, Upham JW, James AL, Marks GB, Gibson PG.Respirology. 2017 Jan;22(1):53-60. doi: 10.1111/resp.12957. Epub 2016 Nov 30.PMID: 27905186 Review.

Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases.

J Jackson D, Akuthota P, Andradas R, J Bredenoord A, Cordell A, Gray S, Kullman J, Mathur SK, Pavord I, Roufosse F, Rubio C, Rusek IC, Simon D, Strobel MJ, Winders T.Immunotherapy. 2023 May 17. doi: 10.2217/imt-2022-0312. Online ahead of print.PMID: 37194573 Review.

Cited by

Oral Corticosteroid Abuse and Self-Prescription in Italy: A Perspective from Community Pharmacists and Sales Reports before and during the COVID-19 Era.

Nappi E, Keber E, Paoletti G, Casini M; SGCP Group; Carosio C, Romano F, Floris N, Parmigiani C, Salvioni C, Malvezzi L, Puggioni F, Canonica GW, Heffler E, Giua C.J Pers Med. 2023 May 15;13(5):833. doi: 10.3390/jpm13050833.PMID: 37241004 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2021 Fontana, WI: Global Initiative for Asthma; 2021. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V.... Accessed June 2022.
  2.  
    1. Stanford RH, Shah MB, D'Souza AO, Dhamane AD, Schatz M. Short-acting beta-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–407. doi: 10.1016/j.anai.2012.08.014. - DOI - PubMed
  3.  
    1. Spanish Society of Health Directors (SEDISA). Proyecto carabela: Caracterización del modelo asistencial de asma grave para la mejora de la eficiencia de las unidades de asma. 2021. https://sedisa.net/2021/02/09/proyecto-carabela-caracterizacion-del-mode.... Accessed June 2022.
  4.  
    1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_.... Accessed June 2022.
  5.  
    1. Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global sabina programme. Eur Respir J. 2020;55(4):1901872. - PMC - PubMed
  6.  
    1. Asthma + Lung UK. A network-based approach for specialised severe asthma services a proposal to support specialised commissioning for adult severe asthma services. NHS England. 2014.
  7.  
    1. Beekman M, Hales J, Al-Ahmad M, del Olmo R, Tan TL. Breaking the vicious circle – the asthma referral identifier (referid) tool. npj Prim Care Respir Med. 2022;32:40. - PMC - PubMed
  8.  
    1. Buddy Njere A. Transforming patient experience: using digital tools to support people living with asthma. 2021. https://www.astrazeneca.com/media-centre/articles/2021/Vik-asthma-transf.... Accessed June 2022.
  9.  
    1. Nannini LJ. Asthma paradoxes: time for a new approach across the spectrum of asthma severity. Eur Respir J. 2019;53(4):1802329. - PubMed
  10.  
    1. Sole D, Aranda CS, Wandalsen GF. Asthma: epidemiology of disease control in Latin America-short review. Asthma Res Pract. 2017;3:4. doi: 10.1186/s40733-017-0032-3. - DOI - PMC - PubMed
  11.  
    1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2022 report. 2022: https://ginasthma.org/wp-content/uploads/2022/05/GINA-Main-Report-2022-F.... Accessed June 2022.
  12.  
    1. Forum of International Respiratory Societies. The global impact of respiratory disease. European Respiratory Society. 2021. http://www.firsnet.org/images/publications/FIRS_Master_09202021.pdf. Accessed 15 June 2022.
  13.  
    1. Enilari O, Sinha S. The global impact of asthma in adult populations. Ann Glob Health. 2019;85(1):2. doi: 10.5334/aogh.2412. - DOI - PMC - PubMed
  14.  
    1. D'Amato G, Vitale C, Molino A, et al. Asthma-related deaths. Multidiscipl Respir Med. 2016;11:37. doi: 10.1186/s40248-016-0073-0. - DOI - PMC - PubMed
  15.  
    1. World Health Organization. Asthma fact sheet. 2021. https://www.who.int/news-room/fact-sheets/detail/asthma. Accessed June 2022.
  16.  
    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0. - DOI - PubMed
  17.  
    1. Global Asthma Network. The global asthma report. 2014.
  18.  
    1. Menzies-Gow A, Canonica GW, Winders TA, Correia de Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther. 2018;35(10):1485–1496. doi: 10.1007/s12325-018-0777-y. - DOI - PMC - PubMed
  19.  
    1. Royal College of Physicians. Why asthma still kills. The national review of asthma deaths (nrad). 2014.
  20.  
    1. Carr TF, Bleecker E. Asthma heterogeneity and severity. World Allergy Organ J. 2016;9(1):41. doi: 10.1186/s40413-016-0131-2. - DOI - PMC - PubMed
  21.  
    1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi: 10.1183/09031936.00202013. - DOI - PubMed
  22.  
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
  23.  
    1. Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157(4):790–804. doi: 10.1016/j.chest.2019.10.053. - DOI - PubMed
  24.  
    1. Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the US Severe Asthma Registry in the biologic era. Thorax. 2021;76(3):220–227. doi: 10.1136/thoraxjnl-2020-215168. - DOI - PMC - PubMed
  25.  
    1. Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M. The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102–1112. doi: 10.1164/rccm.201901-0016OC. - DOI - PMC - PubMed
  26.  
    1. Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075–2088. doi: 10.1080/03007995.2018.1505352. - DOI - PubMed
  27.  
    1. European Federation of Allergy and Airways Diseases Patients Associations. A European patient perspective on severe asthma: fighting for breath. 2012. https://www.efanet.org/images/2012/07/Fighting_For_Breath1.pdf. Accessed 15 June 2022.
  28.  
    1. Asthma + Lung UK. Do no harm: safer and better treatment options for people with asthma. 2020. https://www.asthma.org.uk/418cbc36/globalassets/campaigns/publications/s.... Accessed June 2022.
  29.  
    1. Menzies-Gow A, Szefler SJ, Busse WW. The relationship of asthma biologics to remission for asthma. J Allergy Clin Immunol Pract. 2021;9(3):1090–1098. doi: 10.1016/j.jaip.2020.10.035. - DOI - PubMed
  30.  
    1. Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther. 2022;39(5):2065–84. - PMC - PubMed
  31.  
    1. World Allergy Organization. The management of severe asthma: economic analysis of the cost of treatments for severe asthma. 2005. https://www.worldallergy.org/educational_programs/world_allergy_forum/an.... Accessed June 2022.
  32.  
    1. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24. doi: 10.1186/1471-2466-9-24. - DOI - PMC - PubMed
  33.  
    1. Reibman J, Tan L, Ambrose C, et al. Clinical and economic burden of severe asthma among us patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127(3):318–325.e2. doi: 10.1016/j.anai.2021.03.015. - DOI - PubMed
  34.  
    1. Centre of Excellence in Severe Asthma. Centre of excellence in severe asthma: Home 2016. https://www.severeasthma.org.au/. Accessed June 2022.
  35.  
    1. O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax. 2015;70(4):376–378. doi: 10.1136/thoraxjnl-2013-204114. - DOI - PubMed
  36.  
    1. Kamphuis B, Efthymiadou O, Kanavos P, Tzouma V. Severe asthma care and treatment: indicators and data for performance management across ten countries. LSE Research Online 2021.
  37.  
    1. Janson C, Henderson R, Lofdahl M, Hedberg M, Sharma R, Wilkinson AJK. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020;75(1):82–84. doi: 10.1136/thoraxjnl-2019-213744. - DOI - PMC - PubMed
  38.  
    1. Wilkinson AJK, Anderson G. Sustainability in inhaled drug delivery. Pharmaceut Med. 2020;34(3):191–199. - PubMed
  39.  
    1. Wilkinson AJK, Braggins R, Steinbach I, Smith J. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019;9(10):e028763. doi: 10.1136/bmjopen-2018-028763. - DOI - PMC - PubMed
  40.  
    1. Kponee-Shovein K, Marvel J, Ishikawa R, et al. Carbon footprint and associated costs of asthma exacerbation care among Uk adults. J Med Econ. 2022;25(1):524–531. doi: 10.1080/13696998.2022.2063603. - DOI - PubMed
  41.  
    1. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. - PubMed
  42.  
    1. Efthymiadou Olina BK, Kanavos P, Tzouma V. Treatment gaps in severe asthma across nine OECD countries and recommendations for addressing them. London: London School of Economics; 2021.
  43.  
    1. Cloutier MM, Salo PM, Akinbami LJ, et al. Clinician agreement, self-efficacy, and adherence with the guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol Pract. 2018;6(3):886–894.e4. doi: 10.1016/j.jaip.2018.01.018. - DOI - PMC - PubMed
  44.  
    1. Mathioudakis AG, Tsilochristou O, Adcock IM, et al. ERS/EAACI statement on adherence to international adult asthma guidelines. Eur Respir Rev. 2021;30(161):210132. - PMC - PubMed
  45.  
    1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680–2688.e7. doi: 10.1016/j.jaip.2021.02.059. - DOI - PubMed
  46.  
    1. Lombardi C, Gani F, Berti A, Comberiati P, Peroni D, Cottini M. Asthma and COVID-19: a dangerous liaison? Asthma Res Pract. 2021;7(1):9. doi: 10.1186/s40733-021-00075-z. - DOI - PMC - PubMed
  47.  
    1. Dolby T, Nafilyan V, Morgan A, Kallis C, Sheikh A, Quint JK. Relationship between asthma and severe COVID-19: a national cohort study. Thorax. 2022. 10.1136/thoraxjnl-2021-218629. - PMC - PubMed
  48.  
    1. Cataldo D, Louis R, Michils A, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2020;58(4):448–458. doi: 10.1080/02770903.2019.1705335. - DOI - PubMed
  49.  
    1. Price D, Bjermer L, Bergin DA, Martinez R. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy. 2017;10:209–223. doi: 10.2147/JAA.S134300. - DOI - PMC - PubMed
  50.  
    1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2019 update). 2019. http://ginasthma.org/gina-reports/. Accessed June 2022.
  51.  
    1. Humbert M, Bourdin A, Papadopoulos NG, et al. Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. J Asthma. 2021;58(7):849–54. - PubMed
  52.  
    1. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008;102(12):1681–1693. doi: 10.1016/j.rmed.2008.08.003. - DOI - PubMed
  53.  
    1. Ryan D, Murphy A, Stallberg B, Baxter N, Heaney LG. 'Simples': a structured primary care approach to adults with difficult asthma. Prim Care Respir J. 2013;22(3):365–373. doi: 10.4104/pcrj.2013.00075. - DOI - PMC - PubMed
  54.  
    1. Haughney J, Winders TA, Holmes S, et al. Global quality standard for identification and management of severe asthma. Adv Ther. 2020;37(9):3645–3659. doi: 10.1007/s12325-020-01450-7. - DOI - PMC - PubMed
  55.  
    1. National Institute for Health and Care Excellence (NICE). Management of suspected rheumatoid arthritis. 2013.
  56.  
    1. National Health Service England. Delivering cancer waiting times. 2015.
  57.  
    1. Partnership for Health System Sustainability and Resilience. A blueprint for change how changes in chronic airways disease care can support the development of a more sustainable and resilient health system. 2021.
  58.  
    1. Asthma Society of Canada. Severe asthma: Canadian Patient Journey. 2017.
  59.  
    1. Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission- what is it and how can it be achieved? Eur Respir J. 2022. 10.1183/13993003.02583-2021. - PubMed
  60.  
    1. Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi: 10.1007/s12016-018-8712-1. - DOI - PMC - PubMed
  61.  
    1. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–792. doi: 10.1080/14728222.2020.1783242. - DOI - PubMed
  62.  
    1. Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–164.e1. doi: 10.1016/j.jaip.2018.04.043. - DOI - PubMed
  63.  
    1. Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma reality—a study: initial analysis. Eur Respir J. 2020;56(4):2000151. - PMC - PubMed
  64.  
    1. Llanos JP, Ortega H, Bogart M, et al. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;13:77–87. doi: 10.2147/JAA.S236609. - DOI - PMC - PubMed
  65.  
    1. Kavanagh J, Jackson DJ, Kent BD. Over- and under-diagnosis in asthma. Breathe (Sheff) 2019;15(1):e20–e27. doi: 10.1183/20734735.0362-2018. - DOI - PMC - PubMed
  66.  
    1. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400. doi: 10.1016/S0140-6736(17)30879-6. - DOI - PubMed
  67.  
    1. Woolcock Institute HMRI, and Asthma Australia. A qualitative study of the lived experience of Australians with severe asthma. 2016.
  68.  
    1. Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res. 2015;24(3):631–639. doi: 10.1007/s11136-014-0801-x. - DOI - PubMed
  69.  
    1. O'Byrne PM, Pedersen S, Schatz M, et al. The poorly explored impact of uncontrolled asthma. Chest. 2013;143(2):511–523. doi: 10.1378/chest.12-0412. - DOI - PubMed
  70.  
    1. Wilkinson A, Maslova E, Janson C, et al. Environmental sustainability in respiratory care: an overview of the healthCARe-Based envirONmental cost of treatment (CARBON) programme. Adv Ther. 2022;39(5):2270–2280. doi: 10.1007/s12325-022-02076-7. - DOI - PMC - PubMed
  71.  
    1. Ambrose CS, Chipps BE, Moore WC, et al. The chronicle study of us adults with subspecialist-treated severe asthma: objectives, design, and initial results. Pragmat Obs Res. 2020;11:77–90. - PMC - PubMed
  72.  
    1. Soong W, Chipps BE, O'Quinn S, et al. Health-related quality of life and productivity among us patients with severe asthma. J Asthma Allergy. 2021;14:713–725. doi: 10.2147/JAA.S305513. - DOI - PMC - PubMed
  73.  
    1. Caminati M, Morais-Almeida M, Bleecker E, et al. Biologics and global burden of asthma: a worldwide portrait and a call for action. World Allergy Organ J. 2021;14(2):100502. doi: 10.1016/j.waojou.2020.100502. - DOI - PMC - PubMed
  74.  
    1. George M, Graff C, Bombezin-Domino A, Pain E. Patients with severe uncontrolled asthma: perception of asthma control and its management. Pulm Ther. 2022;8(2):209–223. doi: 10.1007/s41030-022-00190-z. - DOI - PMC - PubMed
  75.  
    1. Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25(2):161–172. doi: 10.1111/resp.13730. - DOI - PMC - PubMed
  76.  
    1. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi: 10.2147/JAA.S176026. - DOI - PMC - PubMed
  77.  
    1. Suehs CM, Menzies-Gow A, Price D, et al. Expert consensus on the tapering of oral corticosteroids for the treatment of asthma: a Delphi study. Am J Respir Crit Care Med. 2021;203(7):871–81. - PubMed
  78.  
    1. Blakey J, Chung LP, McDonald VM, et al. Oral corticosteroids stewardship for asthma in adults and adolescents: a position paper from the Thoracic Society of Australia and New Zealand. Respirology. 2021;26(12):1112–1130. doi: 10.1111/resp.14147. - DOI - PMC - PubMed
  79.  
    1. Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75. - PMC - PubMed
  80.  
    1. Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. - PubMed
  81.  
    1. Ekstrom M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74(11):2181–2190. doi: 10.1111/all.13874. - DOI - PMC - PubMed
  82.  
    1. Hyland ME, Jones RC, Lanario JW, Masoli M. The construction and validation of the severe asthma questionnaire. Eur Respir J. 2018;52(1):1800618. doi: 10.1183/13993003.00618-2018. - DOI - PMC - PubMed
  83.  
    1. Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. Eur Respir Rev. 2020;29(155):190151. - PMC - PubMed
  84.  
    1. Tran TN, Maclachlan S, Hicks W, et al. Oral corticosteroid treatment patterns of patients in the United States with persistent asthma. J Allergy Clin Immunol Pract. 2021;9(1):338–346.e3. doi: 10.1016/j.jaip.2020.06.019. - DOI - PubMed
  85.  
    1. Boulet L-P, Godbout K. Oral corticosteroids tapering in severe asthma. Am J Respir Crit Care Med. 2021;203(7):795–796. doi: 10.1164/rccm.202010-4001ED. - DOI - PMC - PubMed
  86.  
    1. Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37–42. doi: 10.1016/j.anai.2015.10.027. - DOI - PubMed
  87.  
    1. Kaynak U, van Rhijn PC. Patient perspective on severe asthma; insights into the patient journey. The Lung Week. April 9–12, 2018, Ermelo, the Netherlands. https://www.weekvandelongen.nl/nl/abstracts.April. Accessed June 2022.
  88.  
    1. Clark VL, Gibson PG, McDonald VM. What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. ERJ Open Res. 2021;7(1):00497-2020. - PMC - PubMed
  89.  
    1. Fiks AG, Mayne SL, Karavite DJ, et al. Parent-reported outcomes of a shared decision-making portal in asthma: a practice-based RCT. Pediatrics. 2015;135(4):e965–973. doi: 10.1542/peds.2014-3167. - DOI - PMC - PubMed
  90.  
    1. Kew KM, Malik P, Aniruddhan K, Normansell R. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017;10:CD012330. - PMC - PubMed
  91.  
    1. Pollard S, Bansback N, FitzGerld JM, Bryan S. The burden of nonadherence among adults with asthma: a role for shared decision-making. Allergy. 2017;72(5):705–712. doi: 10.1111/all.13090. - DOI - PubMed
  92.  
    1. Black RJ, Lester S, Buchbinder R, et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther. 2017;19(1):253. - PMC - PubMed

Page Navigation